CoChat

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer

Open access
Bueschbell, Beatriz, Caniceiro, Ana Beatriz, Suzano, Pedro M.S., Machuqueiro, Miguel, Rosário-Ferreira, Nícia, Moreira, Irina S. · 2022 · Drug Resistance Updates
Cited by 37

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Globally with over 10 million deaths per year, cancer is the most transversal disease across countries, cultures, and ethnicities, affecting both developed and developing regions. Tumorigenesis is dynamically altered by distinct events and can be lethal when untreated. Despite the innovative therapeutics available, multidrug resistance (MDR) to chemotherapy remains the major hindrance to the success of cancer therapy. The multiple mechanisms by which cancer cells evade cell death are diverse, indicating that MDR involves complex interconnected biological networks. Molecular profiling is currently able to stratify cancer into its distinct subtypes and help identify the best therapeutics, leading to "translational systems medicine". Highly specialized methodologies are generating a large amount of "omics" data - including epigenetics, genomics, transcriptomics, proteomics, metabolomics, as well as pharmacogenomics. Many of the resulting databases store data in non-standard formats, which need to be converted, interpreted, and merged into readable formats. The latest development of artificial intelligence (AI) methodologies and tools, coupled with advancements in large-scale data management and powerful graphic processing computing units, potentiate the integration of these large data sources into relevant biological networks, which will enhance our understanding of cancer MDR. In this review, we revisit common MDR mechanisms and compile a list of the most relevant "omics" public databases. We highlight examples of AI methods that are now decisively contributing to clear advances in cancer research, such as identification of new drugs from large databases and prediction of relevant drug, target, and system properties. An overview of several freely available "ready-to-use" algorithms is also provided. The described molecular scale AI algorithms and tools will undoubtedly guide important improvements in efficiency and efficacy of traditional methods of cancer diagnostics and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drup.2022.100811

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 518

  1. Akao, 2014, Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells, Int. J. Mol. Sci., 15, 1392, 10.3390/ijms15011392 · DOI
  2. Akesson, 2004, Integration of gene expression data into genome-scale metabolic models, Metab. Eng., 6, 285, 10.1016/j.ymben.2003.12.002 · DOI · Paper page
  3. Akhand, 2015, Context likelihood of relatedness with maximal information coefficient for Gene regulatory network inference, 2015 18th International Conference on Computer and Information Technology (ICCIT), 312
  4. Alaoui-Jamali, 2004, Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling, Drug Resist. Updat., 7, 245, 10.1016/j.drup.2004.06.004 · DOI
  5. Aldrich, 1979, Pleiotropic phenotype of cultured murine cells resistant to Maytansine, vincristine, colchicine, and Adriamycin23, J. Natl. Cancer Inst., 63, 751, 10.1093/jnci/63.3.751 · doi:10.1093/jnci/63.3.751
  6. Alexov, 2011, Progress in the prediction of pKa values in proteins, Proteins, 79, 3260, 10.1002/prot.23189 · DOI · Paper page
  7. Alfarouk, 2011, Tumor acidity as evolutionary spite, Cancers, 3, 408, 10.3390/cancers3010408 · DOI
  8. Alfarouk, 2015, Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, Cancer Cell Int., 15, 71, 10.1186/s12935-015-0221-1 · DOI · Paper page
  9. Allison, 1974, Lysosomes in cancer cells, J. Clin. Pathol. Suppl., 7, 43, 10.1136/jcp.s3-7.1.43 · doi:10.1136/jcp.s3-7.1.43
  10. Al-Nedawi, 2008, Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells, Nat. Cell Biol., 10, 619, 10.1038/ncb1725 · DOI · Paper page
  11. Alonso-López, 2016, APID interactomes: providing proteome-based interactomes with controlled quality for multiple species and derived networks, Nucleic Acids Res., 44, W529, 10.1093/nar/gkw363 · DOI · Paper page
  12. Altelaar, 2012, Trends in ultrasensitive proteomics, Curr. Opin. Chem. Biol., 16, 206, 10.1016/j.cbpa.2011.12.011 · DOI
  13. Alvares, 2021, Modulatory effects of acidic pH and membrane potential on the adsorption of pH-Sensitive peptides to anionic lipid membrane, Membranes, 11
  14. An, 2017, Regulation of multidrug resistance by microRNAs in anti-cancer therapy, Acta Pharm. Sin. B, 7, 38, 10.1016/j.apsb.2016.09.002 · DOI · Paper page
  15. Anandakrishnan, 2012, H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations, Nucleic Acids Res., 40, W537, 10.1093/nar/gks375 · DOI · Paper page
  16. Andrei, 2020, Advanced technological tools to study multidrug resistance in cancer, Drug Resist. Updat., 48, 10.1016/j.drup.2019.100658 · DOI
  17. Anemone, 2019, Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH, Cancer Metastasis Rev., 38, 25, 10.1007/s10555-019-09782-9 · DOI · Paper page
  18. Antonioli, 2013, CD39 and CD73 in immunity and inflammation, Trends Mol. Med., 19, 355, 10.1016/j.molmed.2013.03.005 · DOI · Paper page
  19. Antosiewicz, 2020, Constant-pH brownian dynamics simulations of a protein near a charged surface, ACS Omega, 5, 30282, 10.1021/acsomega.0c04817 · DOI
  20. Anusuya, 2018, Drug-target interactions: prediction methods and applications, Curr. Protein Pept. Sci., 19, 537, 10.2174/1389203718666161108091609 · DOI
  21. Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat., 46, 10.1016/j.drup.2019.100645 · DOI · Paper page
  22. Balbin, 2013, Abstract 5214: reconstructing targetable pathways in KRAS dependent lung cancer by integrating transcriptome, proteome and phosphoproteome, Mol. Cell. Biol.
  23. Baldo, 2013, Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch, Cancer Metastasis Rev., 32, 723, 10.1007/s10555-013-9447-3 · DOI
  24. Baptista, 2002, Constant-pH molecular dynamics using stochastic titration, J. Chem. Phys., 117, 4184, 10.1063/1.1497164 · DOI · Paper page
  25. Barbarino, 2018, PharmGKB: a worldwide resource for pharmacogenomic information, Wiley Interdiscip. Rev. Syst. Biol. Med., 10, e1417, 10.1002/wsbm.1417 · DOI · Paper page
  26. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  27. Barrett, 2013, NCBI GEO: archive for functional genomics data sets--update, Nucleic Acids Res., 41, D991, 10.1093/nar/gks1193 · DOI · Paper page
  28. Bar-Zeev, 2017, Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance, Drug Resist. Updat., 31, 15, 10.1016/j.drup.2017.05.002 · DOI · Paper page
  29. Bashashati, 2013, Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling, J. Pathol., 231, 21, 10.1002/path.4230 · DOI · Paper page
  30. Baskin, 1981, Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells, Proc. Natl. Acad. Sci. U. S. A., 78, 3654, 10.1073/pnas.78.6.3654 · doi:10.1073/pnas.78.6.3654
  31. Bebawy, 2009, Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells, Leukemia, 23, 1643, 10.1038/leu.2009.76 · DOI · Paper page
  32. Berglund, 2021, Accessible pipeline for translational research using TCGA: examples of relating gene mechanism to disease-specific outcomes, Methods Mol. Biol., 2194, 127, 10.1007/978-1-0716-0849-4_8 · DOI
  33. Bhattacharya, 2014, GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways, PLoS One, 9, 10.1371/journal.pone.0114409 · DOI
  34. Bhola, 2013, TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer, J. Clin. Invest., 123, 1348, 10.1172/JCI65416 · DOI · Paper page
  35. Binenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updat., 23, 55, 10.1016/j.drup.2015.10.002 · DOI · Paper page
  36. Blagosklonny, 2004, Analysis of FDA approved anticancer drugs reveals the future of cancer therapy, Cell Cycle, 3, 1035, 10.4161/cc.3.8.1023 · DOI
  37. Bleakley, 2009, Supervised prediction of drug-target interactions using bipartite local models, Bioinformatics, 25, 2397, 10.1093/bioinformatics/btp433 · DOI · Paper page
  38. Bonacich, 1987, Power and centrality: a family of measures, Am. J. Sociol., 92, 1170, 10.1086/228631 · DOI · Paper page
  39. Booth, 1961, An enzyme from rat liver catalysing conjugations with glutathione, Biochem. J., 79, 516, 10.1042/bj0790516 · DOI · Paper page
  40. Borst, 2012, Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?, Open Biol., 2, 10.1098/rsob.120066 · DOI · Paper page
  41. Bouvy, 2017, Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo, Leuk. Res., 62, 70, 10.1016/j.leukres.2017.09.014 · DOI
  42. Brabbs, 1979, Isolation and characterization of bleomycin-resistant clones of CHO cells, Genet. Res., 34, 269, 10.1017/S0016672300019509 · doi:10.1017/s0016672300019509
  43. Bradley, 1988, Mechanism of multidrug resistance, Biochim. Biophys. Acta, 948, 87
  44. Bulusu, 2014, canSAR: updated cancer research and drug discovery knowledgebase, Nucleic Acids Res., 42, D1040, 10.1093/nar/gkt1182 · DOI · Paper page
  45. Burnstock, 2013, Purinergic signalling and cancer, Purinergic Signal., 9, 491, 10.1007/s11302-013-9372-5 · DOI · Paper page
  46. Burrell, 2014, Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol. Oncol., 8, 1095, 10.1016/j.molonc.2014.06.005 · DOI · Paper page
  47. Cai, 2021, Protein pKa prediction with machine learning, ChemRxiv
  48. Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 · DOI · Paper page
  49. Cancer Genome Atlas Research Network, 2013, The Cancer genome atlas pan-cancer analysis project, Nat. Genet., 45, 1113, 10.1038/ng.2764 · DOI · Paper page
  50. Cao, 2020, Towards the overcoming of anticancer drug resistance mediated by p53 mutations, Drug Resist. Updat., 49, 10.1016/j.drup.2019.100671 · DOI · Paper page
  51. Care, 2019, Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer, NPJ Syst. Biol. Appl., 5, 13, 10.1038/s41540-019-0090-7 · DOI
  52. Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
  53. Challagundla, 2015, Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy, J. Natl. Cancer Inst., 107
  54. Charitou, 2016, Using biological networks to integrate, visualize and analyze genomics data, Genet. Sel. Evol., 48, 27, 10.1186/s12711-016-0205-1 · DOI
  55. Chatterjee, 2018, The multifaceted role of glutathione S-transferases in cancer, Cancer Lett., 433, 33, 10.1016/j.canlet.2018.06.028 · DOI · Paper page
  56. Checa-Rojas, 2018, GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer, Oncotarget, 9, 21696, 10.18632/oncotarget.24796 · DOI
  57. Chen, 2007, Key aspects of analyzing microarray gene-expression data, Pharmacogenomics, 8, 473, 10.2217/14622416.8.5.473 · DOI
  58. Chen, 2002, TTD: therapeutic target database, Nucleic Acids Res., 30, 412, 10.1093/nar/30.1.412 · DOI · Paper page
  59. Chen, 2014, Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs, Tumour Biol., 35, 9649, 10.1007/s13277-014-2242-0 · DOI
  60. Chen, 2014, Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs, PLoS One, 9
  61. Chen, 2015, The Warburg effect: evolving interpretations of an established concept, Free Radic. Biol. Med., 79, 253, 10.1016/j.freeradbiomed.2014.08.027 · DOI · Paper page
  62. Chen, 2017, Long non-coding RNAs in anti-cancer drug resistance, Oncotarget, 8, 1925, 10.18632/oncotarget.12461 · DOI · Paper page
  63. Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J. Biomed. Inform., 85, 149, 10.1016/j.jbi.2018.07.024 · DOI · Paper page
  64. Chen, 2021, Establishing a consensus for the hallmarks of cancer based on gene ontology and pathway annotations, BMC Bioinformatics, 22, 178, 10.1186/s12859-021-04105-8 · DOI
  65. Cheng, 2019, Network-based prediction of drug combinations, Nat. Commun., 10, 1197, 10.1038/s41467-019-09186-x · DOI · Paper page
  66. Chitnis, 1978, Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis, J. Natl. Cancer Inst., 60, 1049, 10.1093/jnci/60.5.1049 · doi:10.1093/jnci/60.5.1049
  67. Chiu, 2018, scdNet: a computational tool for single-cell differential network analysis, BMC Syst. Biol., 12, 124, 10.1186/s12918-018-0652-0 · DOI
  68. Chiu, 2019, Correction to: predicting drug response of tumors from integrated genomic profiles by deep neural networks, BMC Med. Genomics
  69. Choi, 2014, ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development, Curr. Pharm. Des., 20, 793, 10.2174/138161282005140214165212 · DOI · Paper page
  70. Cieślik, 2018, Cancer transcriptome profiling at the juncture of clinical translation, Nat. Rev. Genet., 19, 93, 10.1038/nrg.2017.96 · DOI · Paper page
  71. Cohen, 2021, Targeted nanomedicine modalities for prostate cancer treatment, Drug Resist. Updat., 56, 10.1016/j.drup.2021.100762 · DOI
  72. Collier, 1970, Spotted necrosis of the tarsal conjunctiva in a case of progressive scleroderma, Bull. Soc. Ophtalmol. Fr., 70, 818
  73. Colombo, 2013, Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles, J. Cell. Sci., 126, 5553
  74. Conesa, 2019, Making multi-omics data accessible to researchers, Sci. Data, 6, 251, 10.1038/s41597-019-0258-4 · DOI · Paper page
  75. Connor, 2010, The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib, Thromb. Haemost., 103, 1044, 10.1160/TH09-09-0644 · DOI · Paper page
  76. Consolino, 2020, Non-invasive investigation of tumor metabolism and acidosis by MRI-CEST imaging, Front. Oncol., 10, 161, 10.3389/fonc.2020.00161 · DOI
  77. Corcoran, 2014, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression, Prostate, 74, 1320, 10.1002/pros.22848 · DOI · Paper page
  78. Costa, 2008, Complex networks: the key to systems biology, Genet. Mol. Biol., 31, 591, 10.1590/S1415-47572008000400001 · DOI
  79. Crecelius, 2015, MALDI mass spectrometric imaging meets “omics”: recent advances in the fruitful marriage, Analyst, 140, 5806, 10.1039/C5AN00990A · DOI
  80. Cuellar, 2018, BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, J. Oncol. Pharm. Pract., 24, 433, 10.1177/1078155217710553 · DOI
  81. Cui, 2010, A network of cancer genes with co-occurring and anti-co-occurring mutations, PLoS One, 5
  82. Czowski, 2020, Cancer and pH dynamics: transcriptional regulation, proteostasis, and the need for new molecular tools, Cancers, 12
  83. Daniel, 2013, The role of proton dynamics in the development and maintenance of multidrug resistance in cancer, Biochim. Biophys. Acta, 1832, 606, 10.1016/j.bbadis.2013.01.020 · DOI
  84. Danø, 1995, The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion, Nihon Kessen Shiketsu Gakkai shi, 6, 212, 10.2491/jjsth.6.212 · DOI · Paper page
  85. Das, 2020, Integration of online omics-data resources for Cancer research, Front. Genet., 11, 10.3389/fgene.2020.578345 · DOI
  86. de Angelis, 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil, Int. J. Oncol., 24, 1279
  87. De Angelis, 2006, Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery, Mol. Cancer, 5, 20, 10.1186/1476-4598-5-20 · DOI · Paper page
  88. De Las Rivas, 2018, Human interactomics: comparative analysis of different protein interaction resources and construction of a Cancer protein-Drug bipartite network, Adv. Protein Chem. Struct. Biol., 111, 263, 10.1016/bs.apcsb.2017.09.002 · DOI
  89. Dean, 2005, Tumour stem cells and drug resistance, Nat. Rev. Cancer, 5, 275, 10.1038/nrc1590 · DOI · Paper page
  90. Debenham, 1982, DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression, Mol. Cell. Biol., 2, 881
  91. Deeley, 2006, Substrate recognition and transport by multidrug resistance protein 1 (ABCC1), FEBS Lett., 580, 1103, 10.1016/j.febslet.2005.12.036 · DOI · Paper page
  92. Dekker, 2002, Capturing chromosome conformation, Science, 295, 1306, 10.1126/science.1067799 · DOI · Paper page
  93. Del Conde, 2005, Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation, Blood, 106, 1604, 10.1182/blood-2004-03-1095 · DOI · Paper page
  94. Deli, 2007, Functional genomics of calcium channels in human melanoma cells, Int. J. Cancer, 121, 55, 10.1002/ijc.22621 · DOI
  95. Demel, 2009, Predicting ligand interactions with ABC transporters in ADME, Chem. Biodivers., 6, 1960, 10.1002/cbdv.200900138 · DOI
  96. Deng, 2016, Twist mediates an aggressive phenotype in human colorectal cancer cells, Int. J. Oncol., 48, 1117, 10.3892/ijo.2016.3342 · DOI · Paper page
  97. Desiere, 2005, Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry, Genome Biol., 6, R9, 10.1186/gb-2004-6-1-r9 · DOI · Paper page
  98. Di Virgilio, 2009, P2X(7): a growth-promoting receptor-implications for cancer, Purinergic Signal., 5, 251, 10.1007/s11302-009-9145-3 · DOI
  99. Díez-Villanueva, 2015, Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer, Epigenetics Chromatin, 8, 22, 10.1186/s13072-015-0014-8 · DOI · Paper page
  100. Dixon, 2012, Topological domains in mammalian genomes identified by analysis of chromatin interactions, Nature, 485, 376, 10.1038/nature11082 · DOI · Paper page
  101. Dorman, 2016, Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning, Mol. Oncol., 10, 85, 10.1016/j.molonc.2015.07.006 · DOI · Paper page
  102. Du, 2016, Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in Cancer, Molecules, 21
  103. Edelman, 2017, Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy, Oncotarget, 8, 24337, 10.18632/oncotarget.15363 · DOI
  104. Edgar, 2002, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Res., 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
  105. Edwards, 2015, The CPTAC data portal: a resource for Cancer proteomics research, J. Proteome Res., 14, 2707, 10.1021/pr501254j · DOI · Paper page
  106. Ender, 2019, Extracellular vesicles: subcellular organelles with the potential to spread Cancer resistance, Anticancer Res., 39, 3395, 10.21873/anticanres.13483 · DOI
  107. Engelberg, 2019, Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo, Cell Death Dis., 10, 702, 10.1038/s41419-019-1870-0 · DOI
  108. Engelberg, 2021, Targeted nanoparticles harboring Jasmine-oil-entrapped paclitaxel for elimination of lung cancer cells, Int. J. Mol. Sci., 22, 1019, 10.3390/ijms22031019 · DOI
  109. Eramo, 2006, Chemotherapy resistance of glioblastoma stem cells, Cell Death Differ., 13, 1238, 10.1038/sj.cdd.4401872 · DOI · Paper page
  110. Erić, 2014, Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein, SAR QSAR Environ. Res., 25, 939, 10.1080/1062936X.2014.976265 · DOI
  111. Fais, 2010, Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism, J. Intern. Med., 267, 515, 10.1111/j.1365-2796.2010.02225.x · DOI
  112. Falkner, 2007, ProteomeCommons.oRg IO Framework: reading and writing multiple proteomics data formats, Bioinformatics, 23, 262, 10.1093/bioinformatics/btl573 · DOI
  113. Falzoni, 2013, Detecting adenosine triphosphate in the pericellular space, Interface Focus, 3, 10.1098/rsfs.2012.0101 · DOI · Paper page
  114. Fan, 2020, Single-cell transcriptomics in cancer: computational challenges and opportunities, Exp. Mol. Med., 52, 1452, 10.1038/s12276-020-0422-0 · DOI · Paper page
  115. Federici, 2014, Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin, PLoS One, 9, 10.1371/journal.pone.0088193 · DOI · Paper page
  116. Ferlay, 2021, Cancer statistics for the year 2020: an overview, Int. J. Cancer, 149, 778, 10.1002/ijc.33588 · DOI · Paper page
  117. Filippini, 1990, Extracellular ATP in T-lymphocyte activation: possible role in effector functions, Proc. Natl. Acad. Sci. U. S. A., 87, 8267, 10.1073/pnas.87.21.8267 · DOI · Paper page
  118. Fiore, 2017, Collaboration to accelerate proteogenomics Cancer care: the department of veterans affairs, department of defense, and the national Cancer institute’s applied proteogenomics OrganizationaL learning and outcomes (APOLLO) network, Clin. Pharmacol. Ther., 101, 619, 10.1002/cpt.658 · DOI
  119. Fogolari, 2012, Bluues: a program for the analysis of the electrostatic properties of proteins based on generalized Born radii, BMC Bioinformatics, 13, S18, 10.1186/1471-2105-13-S4-S18 · DOI
  120. Forbes, 2010, COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res., 38, D652, 10.1093/nar/gkp995 · DOI · Paper page
  121. Fotoohi, 2004, Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy, Blood, 104, 4194, 10.1182/blood-2004-04-1493 · doi:10.1182/blood-2004-04-1493
  122. Fouladiha, 2017, Biomedical applications of cell- and tissue-specific metabolic network models, J. Biomed. Inform., 68, 35, 10.1016/j.jbi.2017.02.014 · DOI
  123. Frank, 2010, The therapeutic promise of the cancer stem cell concept, J. Clin. Invest., 120, 41, 10.1172/JCI41004 · DOI · Paper page
  124. Freeman, 1977, A set of measures of centrality based on betweenness, Sociometry, 40, 35, 10.2307/3033543 · DOI · Paper page
  125. Frei, 1961, Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and Methotrexate, Blood, 18, 431, 10.1182/blood.V18.4.431.431 · DOI · Paper page
  126. Fruehauf, 2006, In vitro drug response and molecular markers associated with drug resistance in malignant gliomas, Clin. Cancer Res., 12, 4523, 10.1158/1078-0432.CCR-05-1830 · DOI
  127. Gacche, 2018, Redundant angiogenic signaling and tumor drug resistance, Drug Resist. Updat., 36, 47, 10.1016/j.drup.2018.01.002 · DOI
  128. Galluzzi, 2012, Enlightening the impact of immunogenic cell death in photodynamic cancer therapy, EMBO J., 10.1038/emboj.2012.2 · DOI
  129. Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107 · DOI · Paper page
  130. Ganapathy-Kanniappan, 2013, Tumor glycolysis as a target for cancer therapy: progress and prospects, Mol. Cancer, 12, 152, 10.1186/1476-4598-12-152 · DOI · Paper page
  131. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, l1, 10.1126/scisignal.2004088 · DOI · Paper page
  132. Gao, 2019, Before and after: comparison of legacy and harmonized TCGA genomic data commons’ data, Cell Syst., 9
  133. Gao, 2021, Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function, Drug Resist. Updat., 57, 10.1016/j.drup.2021.100770 · DOI
  134. Garofalo, 2013, MicroRNAs as therapeutic targets in chemoresistance, Drug Resist. Updat., 16, 47, 10.1016/j.drup.2013.05.001 · DOI · Paper page
  135. Geng, 2013, The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer, Diagn. Pathol., 8, 198, 10.1186/1746-1596-8-198 · DOI
  136. Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl. J. Med., 366, 883, 10.1056/NEJMoa1113205 · DOI · Paper page
  137. Gillet, 2010, Mechanisms of multidrug resistance in cancer, Methods Mol. Biol., 596, 47, 10.1007/978-1-60761-416-6_4 · DOI · Paper page
  138. Gillet, 2012, Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma, Clin. Cancer Res., 18, 3197, 10.1158/1078-0432.CCR-12-0056 · DOI
  139. Gilson, 2016, BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res., 44, D1045, 10.1093/nar/gkv1072 · DOI · Paper page
  140. Glaves, 2011, Generation and analysis of transcriptomics data, Methods Mol. Biol., 691, 167, 10.1007/978-1-60761-849-2_10 · doi:10.1007/978-1-60761-849-2_10
  141. Gokcan, 2021, Prediction of protein pKa with representation learning, ChemRxiv.
  142. Goldenberg, 2019, A new era: artificial intelligence and machine learning in prostate cancer, Nat. Rev. Urol., 16, 391, 10.1038/s41585-019-0193-3 · DOI · Paper page
  143. Goldman, 2019, The UCSC Xena platform for public and private cancer genomics data visualization and interpretation, bioRxiv.
  144. Goler-Baron, 2011, Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance, PLoS One, 6, 10.1371/journal.pone.0016007 · DOI
  145. Goler-Baron, 2012, Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells, Biochem. Pharmacol., 83, 1340, 10.1016/j.bcp.2012.01.033 · DOI
  146. Golub, 1999, Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science, 286, 531, 10.1126/science.286.5439.531 · DOI · Paper page
  147. Gomes de Oliveira Dal’Molin, 2015, A multi-tissue genome-scale metabolic modeling framework for the analysis of whole plant systems, Front. Plant Sci., 6, 4
  148. Gonen, 2012, Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance, Drug Resist. Updat., 15, 183, 10.1016/j.drup.2012.07.002 · DOI · Paper page
  149. Gong, 2013, DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data, Bioinformatics, 29, 1083, 10.1093/bioinformatics/btt090 · DOI · Paper page
  150. Gordon, 2012, Cellular senescence and cancer chemotherapy resistance, Drug Resist. Updat., 15, 123, 10.1016/j.drup.2012.01.002 · DOI · Paper page
  151. Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 · DOI · Paper page
  152. Gottesman, 2016, Toward a better understanding of the complexity of Cancer drug resistance, Annu. Rev. Pharmacol. Toxicol., 56, 85, 10.1146/annurev-pharmtox-010715-103111 · DOI · Paper page
  153. Govindarajan, 2012, Microarray and its applications, J. Pharm. Bioallied Sci., 4, S310, 10.4103/0975-7406.100283 · doi:10.4103/0975-7406.100283
  154. Gracie, 2011, An integrated systems biology approach to the study of preterm birth using “-omic” technology--a guideline for research, BMC Pregnancy Childbirth, 11, 71, 10.1186/1471-2393-11-71 · DOI
  155. Graumann, 2012, A framework for intelligent data acquisition and real-time database searching for shotgun proteomics, Mol. Cell Proteomics, 11, 10.1074/mcp.M111.013185 · DOI · Paper page
  156. Greenfield, 2013, Robust data-driven incorporation of prior knowledge into the inference of dynamic regulatory networks, Bioinformatics, 29, 1060, 10.1093/bioinformatics/btt099 · DOI · Paper page
  157. Grillo-Hill, 2015, Increased H+ efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression, Elife, 4
  158. Griss, 2020, ReactomeGSA - efficient multi-omics comparative pathway analysis, Mol. Cell Proteomics, 19, 2115, 10.1074/mcp.TIR120.002155 · DOI · Paper page
  159. Grünewald, 2020, Titratable Martini model for constant pH simulations, J. Chem. Phys., 153, 10.1063/5.0014258 · DOI · Paper page
  160. GTEx Consortium, Laboratory, 2017, Genetic effects on gene expression across human tissues, Nature, 550, 204, 10.1038/nature24277 · DOI · Paper page
  161. Gulhan, 2019, Detecting the mutational signature of homologous recombination deficiency in clinical samples, Nat. Genet., 51, 912, 10.1038/s41588-019-0390-2 · DOI · Paper page
  162. Günakan, 2019, A novel prediction method for lymph node involvement in endometrial cancer: machine learning, Int. J. Gynecol. Cancer, 29, 320, 10.1136/ijgc-2018-000033 · DOI
  163. Guo, 2014, Network-based identification of biomarkers coexpressed with multiple pathways, Cancer Inform., 13, 37
  164. Guo, 2016, SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets, Nucleic Acids Res., 44, D1011, 10.1093/nar/gkv1108 · DOI
  165. Gupta, 2020, tpHusion: an efficient tool for clonal pH determination in Drosophila, PLoS One, 15, 10.1371/journal.pone.0228995 · DOI
  166. Ha, 2019, Prior to initiation of chemotherapy, can we predict breast tumor response? Deep learning convolutional neural networks approach using a breast MRI tumor dataset, J. Digit. Imaging, 32, 693, 10.1007/s10278-018-0144-1 · DOI
  167. Haenisch, 2014, MicroRNAs and their relevance to ABC transporters, Br. J. Clin. Pharmacol., 77, 587, 10.1111/bcp.12251 · DOI
  168. Halling-Brown, 2012, canSAR: an integrated cancer public translational research and drug discovery resource, Nucleic Acids Res., 40, D947, 10.1093/nar/gkr881 · DOI · Paper page
  169. Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  170. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  171. Harguindey, 2005, The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature, Biochim. Biophys. Acta, 1756, 1
  172. Harris, 2019, GPU-Accelerated Implementation of Continuous Constant pH Molecular Dynamics in Amber: pKa Predictions with Single-pH Simulations, J. Chem. Inf. Model., 59, 4821, 10.1021/acs.jcim.9b00754 · DOI · Paper page
  173. Harris, 2020, Predicting reactive cysteines with implicit-solvent-Based continuous constant pH molecular dynamics in amber, J. Chem. Theory Comput., 16, 3689, 10.1021/acs.jctc.0c00258 · DOI
  174. Hashimshony, 2012, CEL-Seq: single-cell RNA-Seq by multiplexed linear amplification, Cell Rep., 2, 666, 10.1016/j.celrep.2012.08.003 · DOI · Paper page
  175. Haslehurst, 2012, EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer, BMC Cancer, 12, 91, 10.1186/1471-2407-12-91 · DOI · Paper page
  176. Hayes, 2005, Glutathione transferases, Annu. Rev. Pharmacol. Toxicol., 45, 51, 10.1146/annurev.pharmtox.45.120403.095857 · DOI · Paper page
  177. Hazai, 2013, Predicting substrates of the human breast cancer resistance protein using a support vector machine method, BMC Bioinformatics, 14, 130, 10.1186/1471-2105-14-130 · DOI
  178. Hein, 2013, Chapter 1 - proteomic analysis of cellular systems, 3
  179. Hermann, 2007, Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer, Cell Stem Cell, 1, 313, 10.1016/j.stem.2007.06.002 · DOI · Paper page
  180. Hinkson, 2017, A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine, Front. Cell Dev. Biol., 5, 83, 10.3389/fcell.2017.00083 · DOI · Paper page
  181. Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
  182. Hoopmann, 2013, Current algorithmic solutions for peptide-based proteomics data generation and identification, Curr. Opin. Biotechnol., 24, 31, 10.1016/j.copbio.2012.10.013 · DOI
  183. Hossain, 2019, Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality, J. Biomed. Inform., 100, 10.1016/j.jbi.2019.103313 · DOI
  184. Housman, 2014, Drug resistance in cancer: an overview, Cancers, 6, 1769, 10.3390/cancers6031769 · DOI · Paper page
  185. Houssein, 2021, Deep and machine learning techniques for medical imaging-based breast cancer: a comprehensive review, Expert Syst. Appl., 167, 10.1016/j.eswa.2020.114161 · DOI · Paper page
  186. Hraběta, 2020, Drug sequestration in Lysosomes as one of the mechanisms of chemoresistance of Cancer cells and the possibilities of its inhibition, Int. J. Mol. Sci., 21
  187. Hsu, 2011, miRTar: an integrated system for identifying miRNA-target interactions in human, BMC Bioinformatics, 12, 300, 10.1186/1471-2105-12-300 · DOI
  188. Hu, 2014, MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells, Tumour Biol., 35, 8953, 10.1007/s13277-014-2158-8 · DOI
  189. Huang, 1997, Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistance in patients with ovarian cancer, Zhonghua Fu Chan Ke Za Zhi, 32, 458
  190. Huang, 2007, Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm, J. Chem. Inf. Model., 47, 1638, 10.1021/ci700083n · DOI · Paper page
  191. Huby, 2005, Gene expression profiling for pharmaceutical safety assessment, Expert Opin. Drug Metab. Toxicol., 1, 247, 10.1517/17425255.1.2.247 · doi:10.1517/17425255.1.2.247
  192. Hurley, 2008, ESCRT complexes and the biogenesis of multivesicular bodies, Curr. Opin. Cell Biol., 20, 4, 10.1016/j.ceb.2007.12.002 · DOI · Paper page
  193. Hussein, 2021, The role of endolysosomal trafficking in anticancer drug resistance, Drug Resist. Updat., 57, 10.1016/j.drup.2021.100769 · DOI
  194. Hwang, 2018, Single-cell RNA sequencing technologies and bioinformatics pipelines, Exp. Mol. Med., 50, 1, 10.1038/s12276-018-0071-8 · DOI · Paper page
  195. Hyduke, 2013, Analysis of omics data with genome-scale models of metabolism, Mol. Biosyst., 9, 167, 10.1039/C2MB25453K · DOI · Paper page
  196. Iadevaia, 2010, Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis, Cancer Res., 70, 6704, 10.1158/0008-5472.CAN-10-0460 · DOI · Paper page
  197. Icard, 2018, How the Warburg effect supports aggressiveness and drug resistance of cancer cells?, Drug Resist. Updat., 38, 1, 10.1016/j.drup.2018.03.001 · DOI · Paper page
  198. Ifergan, 2005, Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance, Cancer Res., 65, 10952, 10.1158/0008-5472.CAN-05-2021 · DOI · Paper page
  199. Institute of Medicine, Board on Health Sciences Policy, Board on Health Care Services, Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, 2012
  200. Jallon, 1975, Beef liver L-Glutamate dehydrogenase mechanism: presteady state study of the catalytic reduction of 2.oXoglutarate by NADPH, Biochem. Biophys. Res. Commun., 67, 1527, 10.1016/0006-291X(75)90200-4 · doi:10.1016/0006-291x(75)90200-4

200 of 518 shown

Cited by

See all 37

Metadata

Authors
Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário-Ferreira, N., & Moreira, I. S.
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2022-01
Volume
60
Pages
100811
ISSN
1368-7646 (ISSN-L)
OpenAlex
W4210487294
Cited by
37
References
83
FWCI
2.99
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • European Regional Development Fund
  • Fundação para a Ciência e a Tecnologia (CEECIND/02300/2017, DSAIPA/DS/0118/2020, LA/P/0058/2020, PD/BD/135179/2017, POCI-01-0145-FEDER-031356, PTDC/QUI-OUT/32243/2017, SFRH/BD/149709/2019, UIDB/04046/2020, UIDB/04539/2020, UIDP/04046/2020)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.